VolitionRX Limited
0.4300+0.01 (+1.25%)
Oct 29, 4:00:00 PM EDT · NYSE American · VNRX · USD
Key Stats
Market Cap
51.23MP/E (TTM)
-Basic EPS (TTM)
-0.24Dividend Yield
0%Recent Filings
8-K
VolitionRx raises $6M via offering
VolitionRx closed a $6.0 million public offering on October 14, 2025, selling 11,550,000 shares and warrants at $0.52 each, with net proceeds of $5.4 million earmarked for R&D, clinical studies, and potential acquisitions. Cash stood at a mere $0.3 million as of September 30, 2025, underscoring the infusion's urgency. Warrants exercise at $0.60 over five years. Yet dilution looms large.
10-Q
Q2 FY2025 results
VolitionRx posted Q2 revenues of $406.7K, edging up 3% y/y but dipping 12% q/q on softer product sales, while services jumped 39% y/y from Nu.Q Discover demand. Operating loss narrowed to $6.3M from $7.0M y/y, thanks to 27% lower R&D spend after wrapping clinical trials and trimming headcount. Net loss improved to $6.3M, or $(0.06) per diluted share on 102.7M shares, versus $(0.08) last year; the EPS tracks with shares outstanding, no anti-dilution flags. Cash burned $10.6M YTD on ops, ending at $2.3M with $6.8M long-term debt and a fresh $7.5M convertible note (net $3.3M after discounts) issued May 2025 for runway. Free cash flow not disclosed in the 10-Q. Yet funding remains tight. Competition in diagnostics heats up.
8-K
VolitionRx Q2 earnings advance
VolitionRx Limited reported Q2 2025 revenue of just over $0.4 million, fueling 15% first-half growth, while net loss dropped 11% for the quarter and 24% for the half versus prior year. Cash burn eased 30% to $10.6 million in operating activities, though cash reserves stood at $2.3 million by June 30, bolstered by a post-quarter $1.2 million direct offering. Yet progress accelerates: confidential talks with over ten firms advance toward a first human diagnostics licensing deal this quarter. Nu.Q® eyes cancer and sepsis markets.
8-K
VolitionRx prices $1.21M offering
VolitionRx closed a $1.21 million registered direct offering on August 1, 2025, selling 156,250 shares to insiders at $0.64 each and 1,734,375 shares plus warrants to existing stockholders at the same combined price. Warrants, exercisable from August 5, 2025, at $0.768 per share, expire in 2030 and could yield another $1.3 million if fully exercised. Funds will fuel research, clinical studies, and potential acquisitions. Insiders skipped warrants, signaling confidence yet caution.
8-K
Authorized shares doubled to 325M
VolitionRx Limited boosted its authorized common shares from 175 million to 325 million, approved by stockholders at the June 18, 2025 annual meeting and effective immediately upon Delaware filing. The move, backed by the board since April, passed with 49.5 million votes for amid 51.6 million shares present. Stockholders also elected eight directors and ratified the auditor. This expands equity flexibility for future needs.
CODX
Co-Diagnostics, Inc.
0.49-0.08
CVRX
CVRx, Inc.
10.81+0.09
NSRX
Nasus Pharma Ltd.
7.75-0.65
NUTX
Nutex Health Inc.
127.83-0.85
NVCR
NovoCure Limited
13.48+0.11
NXL
Nexalin Technology, Inc.
1.55+0.07
QTIH
QT Imaging Holdings, Inc.
6.95-0.12
VRAX
Virax Biolabs Group Limited
0.60+0.01
VTAK
Catheter Precision, Inc.
2.44-0.12
VYCO
Vycor Medical, Inc.
0.15+0.00